联合抑制 EGFR 和 C-RAF 可使晚期胰腺导管腺癌完全消退。
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
机构信息
Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
Bioinformatics Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.
出版信息
Cancer Cell. 2019 Apr 15;35(4):573-587.e6. doi: 10.1016/j.ccell.2019.03.002. Epub 2019 Apr 8.
Abstract
Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7% due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c-RAF expression results in complete regression of a significant percentage of PDAC tumors driven by Kras/Trp53 mutations in genetically engineered mice. Moreover, systemic elimination of these targets induces toxicities that are well tolerated. Response to this targeted therapy correlates with transcriptional profiles that resemble those observed in human PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. These results open the door to the development of targeted therapies for PDAC patients.
摘要
由于缺乏有效的治疗方法，胰腺导管腺癌（PDAC）患者的 5 年生存率仍低于 7%。在这里，我们报告称，在基因工程小鼠中，联合消融 EGFR 和 c-RAF 的表达导致由 Kras/Trp53 突变驱动的 PDAC 肿瘤的显著百分比完全消退。此外，这些靶点的全身性消除会引起毒性反应，但这些毒性反应是可以耐受的。对这种靶向治疗的反应与在人类 PDAC 中观察到的转录谱相似。最后，抑制 EGFR 和 c-RAF 的表达可有效阻止携带 KRAS 和 TP53 突变的九个独立的患者来源异种移植瘤的肿瘤进展。这些结果为 PDAC 患者的靶向治疗的发展开辟了道路。
相似文献
1
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.联合抑制 EGFR 和 C-RAF 可使晚期胰腺导管腺癌完全消退。
Cancer Cell. 2019 Apr 15;35(4):573-587.e6. doi: 10.1016/j.ccell.2019.03.002. Epub 2019 Apr 8.
2
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.碳酸酐酶 9 通过调节 pH 值介导激活 KRAS 的胰腺癌细胞对低氧的存活反应。
Gastroenterology. 2019 Sep;157(3):823-837. doi: 10.1053/j.gastro.2019.05.004. Epub 2019 May 9.
3
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.一种使用YAP和泛RAF抑制剂治疗KRAS突变型胰腺癌的联合策略。
Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.
4
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.双靶点c-Raf和可溶性环氧化物水解酶抑制剂t-CUPM对携带突变型KrasG12D的小鼠胰腺癌生长的抑制作用
Cancer Lett. 2016 Feb 28;371(2):187-93. doi: 10.1016/j.canlet.2015.11.042. Epub 2015 Dec 9.
5
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.Sirt5 缺失导致的代谢重构促进 Kras 诱导的胰腺癌进展。
Gastroenterology. 2021 Nov;161(5):1584-1600. doi: 10.1053/j.gastro.2021.06.045. Epub 2021 Jul 8.
6
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.SETDB1抑制p53介导的细胞凋亡，是小鼠胰腺导管腺癌形成所必需的。
Gastroenterology. 2020 Aug;159(2):682-696.e13. doi: 10.1053/j.gastro.2020.04.047. Epub 2020 Apr 28.
7
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.表皮生长因子受体和 PI3K 的双重靶向治疗克服了胰腺导管腺癌中 PI3K-Akt 致癌依赖性。
Clin Cancer Res. 2014 Aug 1;20(15):4047-58. doi: 10.1158/1078-0432.CCR-13-3377. Epub 2014 Jun 3.
8
Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.在胰腺癌患者来源的异种移植模型中，帕尼单抗与曲妥珠单抗联合治疗可增强对MEK抑制剂曲美替尼的反应。
Neoplasia. 2014 Jul;16(7):562-71. doi: 10.1016/j.neo.2014.06.004.
9
Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.表皮生长因子受体靶向适体载 5-氟尿嘧啶用于胰腺导管腺癌模型的肿瘤特异性递药：一种有效的治疗方法。
Gastroenterology. 2021 Sep;161(3):996-1010.e1. doi: 10.1053/j.gastro.2021.05.055. Epub 2021 Jun 25.
10
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.厄洛替尼与 MEK 抑制剂在 KRAS 野生型人胰腺癌细胞中的协同作用。
Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8.
引用本文的文献
1
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation.处于自抑制和开放单体状态的CRAF/MEK1/14-3-3复合物的冷冻电镜结构揭示了RAF调节的特征。
Nat Commun. 2025 Sep 1;16(1):8150. doi: 10.1038/s41467-025-63227-2.
2
KRAS: the Achilles' heel of pancreas cancer biology.KRAS：胰腺癌生物学的致命弱点。
J Clin Invest. 2025 Aug 15;135(16). doi: 10.1172/JCI191939.
3
Pancreatic Cancer: Pathogenesis and Clinical Studies.胰腺癌：发病机制与临床研究
MedComm (2020). 2025 Apr 2;6(4):e70162. doi: 10.1002/mco2.70162. eCollection 2025 Apr.
4
Quantitative Live Imaging Reveals Phase Dependency of PDAC Patient-Derived Organoids on ERK and AMPK Activity.定量活体成像揭示了胰腺导管腺癌患者来源类器官对ERK和AMPK活性的阶段依赖性。
Cancer Sci. 2025 Mar;116(3):724-735. doi: 10.1111/cas.16439. Epub 2024 Dec 27.
5
Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth.致癌性 KRAS 依赖性基质白细胞介素-33 指导胰腺微环境促进肿瘤生长。
Cancer Discov. 2024 Oct 4;14(10):1964-1989. doi: 10.1158/2159-8290.CD-24-0100.
6
Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.破坏致癌性 c-RAF-PDE8A 复合物代表了一种针对 KRAS-c-RAF 依赖性 PDAC 的差异化治疗方法。
Sci Rep. 2024 Apr 18;14(1):8998. doi: 10.1038/s41598-024-59451-3.
7
Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines.大麻萜酚通过抑制人胰腺导管腺癌细胞系中的 EGFR-RAS 通路诱导自噬细胞死亡。
Int J Mol Sci. 2024 Feb 7;25(4):2001. doi: 10.3390/ijms25042001.
8
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.新型 RAF 靶向治疗方法克服当前临床限制，阻断 RAS/RAF 节点。
Mol Oncol. 2024 Jun;18(6):1355-1377. doi: 10.1002/1878-0261.13605. Epub 2024 Feb 16.
9
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.CRAF 在癌症进展中的作用：从分子机制到精准治疗。
Nat Rev Cancer. 2024 Feb;24(2):105-122. doi: 10.1038/s41568-023-00650-x. Epub 2024 Jan 9.
10
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.靶向 CRAF 激酶的抗癌治疗：进展与机遇。
Mol Cancer. 2023 Dec 18;22(1):208. doi: 10.1186/s12943-023-01903-x.
本文引用的文献
1
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.实时基因组特征分析在晚期胰腺癌精准医疗中的应用
Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.
2
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.类器官分析鉴定胰腺癌化疗的常见应答者。
Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.
3
Pancreatic cancer subtypes: a roadmap for precision medicine.胰腺癌亚型：精准医学的路线图。
Ann Med. 2018 Jun;50(4):277-287. doi: 10.1080/07853890.2018.1453168. Epub 2018 Mar 22.
4
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.c-RAF 消融通过一种不依赖于 MAPK 信号的机制诱导晚期 Kras/Trp53 突变型肺腺癌的消退。
Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27.
5
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.进化途径和 KRAS 剂量决定胰腺癌细胞表型。
Nature. 2018 Feb 1;554(7690):62-68. doi: 10.1038/nature25459. Epub 2018 Jan 24.
6
mutant genetically engineered mouse models of human cancers are genomically heterogeneous.人类癌症的基因突变工程小鼠模型具有基因组异质性。
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10947-E10955. doi: 10.1073/pnas.1708391114. Epub 2017 Dec 4.
7
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.基于患者来源异种移植的肿瘤-基质互作分析揭示的胰腺导管腺癌治疗靶点。
Cell Rep. 2017 Nov 28;21(9):2458-2470. doi: 10.1016/j.celrep.2017.11.003.
8
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.应激激活的NRF2-MDM2级联反应控制胰腺肿瘤进展
Cancer Cell. 2017 Dec 11;32(6):824-839.e8. doi: 10.1016/j.ccell.2017.10.011. Epub 2017 Nov 16.
9
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌的综合基因组特征分析
Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.
10
A Braf kinase-inactive mutant induces lung adenocarcinoma.一种Braf激酶失活突变体诱导肺腺癌。
Nature. 2017 Aug 10;548(7666):239-243. doi: 10.1038/nature23297. Epub 2017 Aug 2.
Zotero 插件